Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)

COVID19 Clinical Trial

— PROTECT  

Official title:

PROTECT: A Randomized Study With Hydroxychloroquine Versus Observational Support for Prevention or Early Phase Treatment of Coronavirus Disease (COVID-19)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04363827
• Other study ID #: IRST100.47
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: May 14, 2020
• Est. completion date: September 2021

Study information

• Verified date: February 2021
• Source: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Italian, superiority, open label cluster-randomised, interventional clinical trial aimed at assessing whether the treatment with Hydroxychloroquine can reduce the percentage of symptomatic subjects compared to observation only in household members/contacts of COVID-19 patients (Group 1) and if the treatment with Hydroxychloroquine could be introduced in early phase COVID-19 population (Group 2).

The participants will be randomised to receive either:

Arm A) hydroxychloroquine vs Arm B) Observation (2:1 randomisation).

Description:

This is an open label, superiority, cluster-randomized Italian interventional clinical trial, evaluating the role of Hydroxychloroquine versus observation only in preventing infection to COVID-19 or treating early phase COVID-19 patients.

Each index case is randomised to either Arm A: Hydroxychloroquine or Arm B: observation in a 2:1 ratio on an open label basis. Participants in the same cluster receive the same intervention.

Study population is constituted by:

Group 1: Severe Acute Respiratory Syndrome (SARS) - Corona Virus (CoV)-2-exposed subjects , as household members/contacts of COVID-19 patients.

Group 2: Patients with COVID-19 asymptomatic or paucisymptomatic in home situation.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 2300
• Est. completion date: September 2021
• Est. primary completion date: June 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or Female, aged >= 18 years

2. SARS-CoV-2-exposed subjects, as household members and/or contacts of COVID-19 patients (Group 1). In this group are included Health care professionals in contact with COVID-19 patients.

or

3. COVID-19 patients, asymptomatic or paucisymptomatic in home situation who are not in treatment with any anti COVID-19 medication (Group 2)

4. Absence of any COVID-19 symptom in last week before randomization (fever >37.5°C, cough, dyspnea) (only for group 1 subjects)

5. Paracetamol treatment is accepted only for group 2.

6. Participant is willing and able to give informed consent for participation in the study (either recorded during a telephonic interview or signed in person) and agrees with the study and its conduct.

Exclusion Criteria:

1. Reported anamnesis for:

1. Intolerance or previous toxicity for hydroxychloroquine/chloroquine

2. Bradycardia or reduction rhythm of heart with arrythmias

3. Ischemic heart disease

4. Retinopathy

5. Congestive heart failure under/with use of diuretics

6. Favism or glucose-6-phosphate dehydrogenase (G6PD) deficiency

7. Diabetes type 1

8. Major comorbidities like advanced chronic kidney disease or dialysis therapy, known history of ventricular arrhythmias, any oncologic/hematologic malignancy.

9. Severe neurological and mental illness

2. Any other contraindication to take hydroxychloroquine

3. Already taking chloroquine, hydroxychloroquine or analogous during the past 3 weeks

4. Use of other antiviral agents in the last 3 weeks

5. Subject with a positive test for SARS-CoV-2 (for Group 1)

6. Pregnant or lactating

7. Current use of medications with known significant drug-drug interactions: digoxin, hypoglycemic agents, anticonvulsant, Cyclosporine, Phenylbutazone, drugs that inhibit CYP2D6

8. Known prolonged QT syndrome or current use of drugs with known QT prolongation

9. Participation in another clinical trial with any investigational agents within 30 days prior to study screening.

Related Conditions & MeSH terms

• Coronavirus Infections
• COVID19
• Hydroxychloroquine
• Prophylaxis
• SARS-CoV-2
• Treatment

Intervention

Drug:
• Hydroxychloroquine
Hydroxychloroquine

Locations

Country	Name	City	State
Italy	Irst Irccs	Meldola	FC

Sponsors (2)

Lead Sponsor	Collaborator
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori	University of Bologna

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the proportion of subjects of Group 1 who become symptomatic and/or swab positive in each arm within 1 month from randomization.	Group 1:The primary endpoint/outcome measure is the proportion of subjects of Group 1 who become symptomatic and/or swab positive in each arm within 1 month from randomization.	within 1 month from randomization
Primary	the proportion of subjects of Group 2 who become swab negative in each arm within 14 days from randomization.	Group 2: The primary endpoint/outcome measure is the proportion of subjects of Group 2 who become swab negative in each arm within 14 days from randomization.	within 14 days from randomization
Secondary	The proportion of subjects with positive swabs in Group 1 within 1 month from randomization in both arms	The proportion of subjects with positive swabs in randomized population of SARS-CoV-2-exposed subjects ( Group 1) within 1 month from randomization in both arms	within 1 month from randomization
Secondary	The proportion of subjects of Group 1 who become symptomatic in each arm within 1 month from randomization	The proportion of subjects of Group 1 who become symptomatic in each arm within 1 month from randomization, in subgroup population identified by stratification factors, class of age and gender.	within 1 month from randomization
Secondary	The proportion of subjects of Group 2 who become swab negative in each arm within 14 days from randomization.	The proportion of subjects of Group 2 who become swab negative in each arm within 14 days from randomization, in subgroup population identified by stratification factors, class of age and gender.	within 14 days from randomization
Secondary	The proportion of subjects of Group 2 who become swab negative in each arm within 1 month from randomization in overall population and in subgroup population	The proportion of subjects of Group 2 who become swab negative in each arm within 1 month from randomization in overall population and in subgroup population identified by stratification factors, class of age and gender.	within 1 month from randomization
Secondary	Absolute and relative frequencies of Serious Adverse Events	Absolute and relative frequencies of Serious Adverse Events (CTCAE version 5.0) in both arms for the Group 1 and Group 2.	up to 10 months
Secondary	Variation in Quality of Life scores in different time points	Variation in Quality of Life scores EQ-5D-5L (EQ-5D descriptive system with 5 severity levels from better to worse, and the EQ visual analogue scale (EQ VAS, scale from 100 to 0, high is better) in different time points (weekly) respect to baseline values in both Group 1 and Group 2 populations.	up to 10 months